Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05118750 · ClinicalTrials.gov registry record · Phase 2
ALTO-300 in Depression
A Phase 2 study, sponsored by Alto Neuroscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT05118750 is a Phase 2 study that has completed, run by Alto Neuroscience. The registered enrollment target is 91 participants.
The verdict
NCT05118750, a Phase 2 study, has completed, sponsored by Alto Neuroscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
Interventions
- DRUG ALTO-300 oral (PO) tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05118750
The ClinicalTrials.gov registry entry for NCT05118750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alto Neuroscience, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALTO-300 oral (PO) tablet is the first listed.
NCT05118750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05118750 about?
NCT05118750 is a clinical study titled "ALTO-300 in Depression". The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
What is the current status of trial NCT05118750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2021-12-13. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT05118750?
The interventions under investigation include: ALTO-300 oral (PO) tablet (DRUG).
Who is sponsoring clinical trial NCT05118750?
This trial is sponsored by Alto Neuroscience, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.